Clinical trials: Flu Vaccination
Influenza
The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of 2012-2013 trivalent seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy older…
- Trial name
- NCT01736709
- Testing
- 2012-2013 trivalent seasonal influenza vaccine
- Where
- China
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1.
- Trial name
- NCT01773928
- Testing
- Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
- Where
- 20 sites in United States
- Volunteers
- 1,928 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Asthma
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma
Trial to assess asthma exacerbation through to the end of the study; and to demonstrate that the efficacy over one season against culture-confirmed influenza-illness; and finally to assess the safety and tolerability of CAIV-T in…
- Trial name
- NCT00192257
- Testing
- CAIV-T and TIV
- Where
- 2 sites in Belgium
- Volunteers
- 2,229 people
- Sponsor
- MedImmune LLC
Healthy Adult Volunteers
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer
The purpose of this study is to test the safety and immune response of a new intranasal vaccine against influenza, called NB-1008.
- Trial name
- NCT01354379
- Testing
- NB-1008, Fluzone IN
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Influenza
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
The purpose of this study were to obtain additional evidence in support of the safety and immunogenicity of a recombinant hemagglutinin (rHA) vaccine in an elderly population, and to establish non-inferiority of the…
- Trial name
- NCT00395174
- Testing
- Influenza Vaccination
- Where
- 7 sites in United States
- Volunteers
- 870 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children
This study is part of an effort to develop an effective vaccination program in children in the event of a pandemic. Study objectives: To describe the safety profiles in the periods following each vaccination in subjects receiving…
- Conditions
- Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections
- Trial name
- NCT00884182
- Testing
- A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
- Where
- 13 sites in Finland
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objective of this study is to assess the safety and immunogenicity of inactivated influenza vaccine (whole virion, Vero cell derived).
- Trial name
- NCT00289510
- Testing
- Inactivated influenza vaccine (whole virion, Vero cell-derived), Inactivated influenza vaccine (egg derived) [licensed control vaccine]
- Where
- 3 sites in Austria, Germany
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Human
Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.
Multicentric study, Phase III; this study is a randomized, participant- and observer-blind, parallel group evaluation to evaluate the immunogenicity, relative efficacy, safety and reactogenicity of a recombinant quadrivalent…
- Trial name
- NCT03460743
- Testing
- Study group - quadrivalent recombinant hemagglutinin influenza vaccine, Control group - quadrivalent inactivated influenza vaccine
- Where
- 11 sites in Mexico
- Volunteers
- 1,556 people, healthy volunteers welcome
- Sponsor
- Laboratorios Liomont
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU…
- Trial name
- NCT05568797
- Testing
- RSVPreF3 OA vaccine, FLU vaccine
- Where
- 37 sites in Belgium, Finland and 3 more
- Volunteers
- 1,045 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03704740
- Testing
- NBP607-QIV, Agrippal
- Where
- South Korea
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.
The goal of this study is to determine whether Fluviral, an inactivated, injectable trivalent influenza vaccine (flu shot) is effective in preventing respiratory illnesses that are severe enough to limit normal daily activities…
- Trial name
- NCT00216242
- Testing
- Influenza virus vaccine (Fluviral)
- Where
- 43 sites in United States
- Volunteers
- 7,400 people, healthy volunteers welcome
- Sponsor
- ID Biomedical Corporation, Quebec
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over
- Trial name
- NCT00329966
- Testing
- Surface Antigen, Inactivated, Influenza (form.2006-07)
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Novartis
Enhancement of Protective Antibody Response After Probiotic Consumption
Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults
the aim of the study is to get evidence for an enhancement of immune status in subjects after probiotics mixture consumption ( lactobacillus gasseri PA 16/8, Bifidobacterrium longum SP 07/3, Bifidobacterium bifidum MF 20/5) based…
- Trial name
- PROBIMMUNE (NCT01652066)
- Testing
- Mixture of probiotics, Mixture of probitiocs
- Where
- France
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Merck Medication Familiale
Influenza
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in elderly subjects.
- Trial name
- NCT01767896
- Testing
- ASP7374, approved egg-derived TIV
- Where
- 3 sites in Japan
- Volunteers
- 1,020 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
- Trial name
- NCT01999842
- Testing
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A
- Where
- 8 sites in United States, Canada
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to < 18 years of age who are at risk of complications of influenza disease due to underlying diseases.
- Trial name
- NCT01998477
- Testing
- TIVc, TIV
- Where
- 16 sites in Italy, Spain
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Virus Infections
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA).
- Trial name
- NCT05045144
- Testing
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 1,586 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Disease
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of a Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, when Administered to Non-Elderly Adults and…
- Trial name
- NCT00316615
- Testing
- influenza vaccine
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Novartis
Influenza, Human
Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents
The purpose of this study is to evaluate the immunogenicity and safety of 'IL-YANG Quadrivalent Seasonal Influenza Vaccine' in healthy Korean children and adolescents.
- Trial name
- NCT03445468
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Pre-filled Syringe
- Where
- South Korea
- Volunteers
- 379 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.